3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Unknown
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cisplatin
504
Cyclophosphamide
353
Radiotherapy
349
Carboplatin
347
Capecitabine
328
Oxaliplatin
319
Paclitaxel
316
Gemcitabine
315
Docetaxel
308
Fluorouracil
281
apatinib
240
Drug Therapy
239
Bevacizumab
224
camrelizumab
212
Etoposide
199
Irinotecan
176
Doxorubicin
174
Dexamethasone
159
Leucovorin
158
sintilimab
140
Pemetrexed
136
Cytarabine
136
pembrolizumab
135
anlotinib
135
toripalimab
124
S 1 (combination)
119
Neoadjuvant Therapy
119
Vincristine
118
Rituximab
114
Radiosurgery
113
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Interventional
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled